Methodological and molecular factors underlying racial disparities in cancer outcomes
癌症结果种族差异背后的方法学和分子因素
基本信息
- 批准号:10554093
- 负责人:
- 金额:$ 5.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AlgorithmsAndrogen ReceptorBreastBreast Cancer PatientBreast Cancer Risk FactorBreast Cancer survivorCancer EtiologyCancer PatientCancer SurvivorCessation of lifeCharacteristicsClinicClinicalClinical TrialsDataData SourcesDiagnosisDiseaseDisease ProgressionDisparityEmigrationsEpidemiologic MethodsEpidemiologyFailureFamiliarityFellowshipFutureGeneral PopulationGeneticGeographyGoalsHormonalIncidenceInequityInterventionKnowledgeLife StyleMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMethodologyMolecularMolecular TargetNonmetastaticNot Hispanic or LatinoOutcomePatientsPlayPopulation-Based RegistryPremenopauseRaceRecurrenceRecurrent Malignant NeoplasmRegistriesResearchResearch PersonnelResearch Project GrantsResourcesRiskRisk FactorsRoleStage at DiagnosisSurvival RateSurvivorsTrainingTreatment FactorWomanattributable mortalityblack menblack patientblack womenbreast cancer progressioncancer carecancer health disparitycancer recurrencecancer subtypescancer survivalcareercareer developmentcurative treatmentsepidemiology studyexperiencefollow-uphormone therapyimprovedinsightmalignant breast neoplasmmenmenopausal hormone therapyminority patientmortalitymortality disparityneoplasm registryneoplastic celloutcome disparitiespopulation basedracial biasracial differenceracial disparityracial diversityracial minorityracial minority populationracial populationreceptor expressionresearch and developmentskillstherapeutic targettreatment effecttumor progression
项目摘要
Project Summary/Abstract
Despite improvements in cancer survival, racial disparities have persisted for both men and women. Although
overall incidence is lower among Black women than White women, mortality is greater; in contrast Black men
have both greater incidence and mortality. Breast and ovarian cancers, which both contribute to the incongruity
among women, are hormonally-driven cancers with overlapping genetic, molecular, and lifestyle risk factors. In
2020, breast cancer was the cause of over 40,000 deaths, while ovarian cancer accounted for nearly 15,000.
Deaths attributable to these cancers occur disproportionately among Black women. Disparities in mortality are
most pronounced among patients initially diagnosed with non-metastatic disease. Among these patients,
cancer recurrence is a necessary precursor to a cancer-specific death. However, recurrence is poorly
understood due to the lack of systematically-collected population-based data. Current estimates of recurrence
risk are based on clinical trial data, clinic-based registries, or algorithms using administrative claims, and
therefore are not representative of all patients, particularly those with less access to specialized trials or clinics.
Accurate population-based estimation of recurrence is critical to fully understand mortality disparities. An
important methodological consideration in population-based estimation is the follow-up of cancer survivors
years after initial diagnosis. Previous studies have suggested racial minority patients are more likely to be lost
to follow-up, biasing race-specific estimates. Aim 1 of this project will investigate how differences in loss to
follow-up bias race-specific, population-based recurrence estimates, using the rich resources of the Georgia
Cancer Registry (GCR), a population-based registry in a large, racially diverse state. The GCR is the first
population-based cancer registry to systematically identify and register recurrences among breast cancer
survivors. Aims 2 and 3 will use existing epidemiologic studies to investigate patient-level drivers underlying
the disparities. Aim 2 will investigate the association between androgen receptor in tumor cells and breast
cancer recurrence among premenopausal women, particularly those with aggressive subtypes that do not
respond to available endocrine therapy and that are more commonly diagnosed in Black women. Aim 3 will
investigate the role of menopausal hormone treatment, and the mediating effects of this exposure on treatment
factors, in ovarian cancer progression, an association that has only been examined in White women. Results
from this research will provide a framework for accurate estimation of population-based recurrence rates,
additional insight into factors contributing to racial disparities in breast and ovarian cancer outcomes, and will
inform future studies aimed at reducing inequities. In addition, the fellowship will provide a rich array of
epidemiologic training, research, and career development that will contribute to the candidate’s ability to be a
successful and independent cancer researcher, with knowledge and skills in a broad array of epidemiologic
methods, familiarity with the clinical underpinnings of cancer care, and understanding of cancer disparities.
项目摘要/摘要
尽管癌症存活率有所提高,但男性和女性的种族差异依然存在。虽然
黑人女性的总体发病率低于白人女性,死亡率更高;相比之下,黑人男性
有更高的发病率和死亡率。乳腺癌和卵巢癌,这两者都是导致这种不和谐的原因
在女性中,是由激素驱动的癌症,具有重叠的遗传、分子和生活方式风险因素。在……里面
2020年,乳腺癌导致40,000多人死亡,而卵巢癌占近15,000人。
可归因于这些癌症的死亡在黑人女性中不成比例地发生。死亡率的差异是
在最初诊断为非转移性疾病的患者中最为明显。在这些患者中,
癌症复发是癌症特有死亡的必要先兆。然而,复发率很低。
由于缺乏系统收集的以人口为基础的数据,因此无法理解。当前对复发的估计
风险基于临床试验数据、基于诊所的注册或使用管理声明的算法,以及
因此,它们不能代表所有患者,特别是那些较少获得专门试验或诊所的患者。
准确的基于人群的复发估计对于充分了解死亡率差异至关重要。一个
基于人群估计的重要方法学考虑是对癌症幸存者的随访
在最初诊断数年后。此前的研究表明,少数族裔患者更有可能走失
为了后续行动,偏向于特定种族的估计。本项目的目标1将调查损失差异如何
利用佐治亚州丰富的资源,针对特定种族的后续偏见,基于人口的复发估计
癌症登记处(GCR),这是一个以人口为基础的登记处,位于一个种族多元化的大州。GCR是第一个
以人群为基础的癌症登记系统地识别和登记乳腺癌复发
幸存者。AIMS 2和3将使用现有的流行病学研究来调查患者层面的驱动因素
不同之处。目的2将研究肿瘤细胞中雄激素受体与乳房的关系
绝经前妇女的癌症复发,特别是那些具有侵袭性亚型的妇女
对可用的内分泌治疗有反应,而且在黑人女性中更常见的诊断。目标3将
调查更年期激素治疗的作用,以及这种暴露对治疗的中介作用。
卵巢癌进展中的因素,这一关联只在白人女性中进行了研究。结果
这项研究将为准确估计基于人群的复发率提供一个框架,
对导致乳腺癌和卵巢癌预后种族差异的其他因素的进一步洞察,并将
为未来旨在减少不平等现象的研究提供信息。此外,该奖学金将提供一系列丰富的
流行病学培训、研究和职业发展将有助于候选人成为
成功和独立的癌症研究人员,具有广泛的流行病学知识和技能
方法,熟悉癌症护理的临床基础,以及对癌症差异的了解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rebecca Nash其他文献
Rebecca Nash的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rebecca Nash', 18)}}的其他基金
Methodological and molecular factors underlying racial disparities in cancer outcomes
癌症结果种族差异背后的方法学和分子因素
- 批准号:
10389941 - 财政年份:2022
- 资助金额:
$ 5.02万 - 项目类别:
相似海外基金
Elucidating The Role Of Androgen Receptor (AR) In Mediating Radioresistance In AR-Positive Breast Cancer
阐明雄激素受体 (AR) 在介导 AR 阳性乳腺癌放射抗性中的作用
- 批准号:
10746200 - 财政年份:2022
- 资助金额:
$ 5.02万 - 项目类别:
Elucidating the role of androgen receptor (AR) in mediating radioresistance in AR-positive breast cancer
阐明雄激素受体 (AR) 在介导 AR 阳性乳腺癌放射抗性中的作用
- 批准号:
10353728 - 财政年份:2022
- 资助金额:
$ 5.02万 - 项目类别:
Development of novel combination treatments for metastatic androgen receptor-positive triple-negative breast cancer
开发转移性雄激素受体阳性三阴性乳腺癌的新型联合疗法
- 批准号:
9898144 - 财政年份:2018
- 资助金额:
$ 5.02万 - 项目类别:
Development of novel combination treatments for metastatic androgen receptor-positive triple-negative breast cancer
开发转移性雄激素受体阳性三阴性乳腺癌的新型联合疗法
- 批准号:
10055959 - 财政年份:2018
- 资助金额:
$ 5.02万 - 项目类别:
Verification of new therapeutic strategies for androgen receptor positive triple-negative breast cancer
雄激素受体阳性三阴性乳腺癌新治疗策略的验证
- 批准号:
17H07023 - 财政年份:2017
- 资助金额:
$ 5.02万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Androgen Receptor and Intersecting Pathways Critical to Breast Cancer Subtypes
雄激素受体和交叉途径对乳腺癌亚型至关重要
- 批准号:
9389972 - 财政年份:2017
- 资助金额:
$ 5.02万 - 项目类别:
Androgen Receptor and Intersecting Pathways Critical to Breast Cancer Subtypes
雄激素受体和交叉途径对乳腺癌亚型至关重要
- 批准号:
9104116 - 财政年份:2015
- 资助金额:
$ 5.02万 - 项目类别:
Selective activation of androgen receptor to treat estrogen receptor positive breast cancer.
选择性激活雄激素受体治疗雌激素受体阳性乳腺癌。
- 批准号:
nhmrc : GNT1084416 - 财政年份:2015
- 资助金额:
$ 5.02万 - 项目类别:
Project Grants
Selective activation of androgen receptor to treat estrogen receptor positive breast cancer.
选择性激活雄激素受体治疗雌激素受体阳性乳腺癌。
- 批准号:
nhmrc : 1084416 - 财政年份:2015
- 资助金额:
$ 5.02万 - 项目类别:
Project Grants
Androgen Receptor and Intersecting Pathways Critical to Breast Cancer Subtypes
雄激素受体和交叉途径对乳腺癌亚型至关重要
- 批准号:
9480928 - 财政年份:2015
- 资助金额:
$ 5.02万 - 项目类别: